The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

This week on Pipeline Moves, we kick off by looking at the termination of a Phase II investigator-led trial of Eli Lilly’s merestinib in solid tumours. Meanwhile, RevImmune terminated a Phase II ...

Eli Lilly has several exciting products in its pipeline, some of which are likely to earn approval in the next five years. Consider two of the company's leading candidates in weight loss ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

Lilly showed that, by acting on a second one called GIP ... will add important optionality to our clinical pipeline, as we ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Helped by a robust drug pipeline, Eli Lilly is a growth stock that looks unstoppable. Investors should ignore the noise with Novo Nordisk and stay the course. Vertex is the only company that ...

ProQR has strategic partnerships with Eli Lilly and the Rett Syndrome Research Trust, enhancing its product pipeline and research funding. What is the current financial status of ProQR?

Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & CompanyTwo lead programs in ...